Moderna, Inc. Stock price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
106.6 USD -3.64% Intraday chart for Moderna, Inc. +2.37% +7.15%
Sales 2024 * 4.22B Sales 2025 * 4.92B Capitalization 42.34B
Net income 2024 * -2.8B Net income 2025 * -1.97B EV / Sales 2024 * 8.92 x
Net cash position 2024 * 4.73B Net cash position 2025 * 3.38B EV / Sales 2025 * 7.92 x
P/E ratio 2024 *
-15.3 x
P/E ratio 2025 *
-21.8 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.37%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Moderna, Inc.

1 day-3.18%
1 week+2.37%
Current month+15.52%
1 month+9.31%
3 months+7.87%
6 months+6.27%
Current year+7.15%
More quotes
1 week
103.51
Extreme 103.51
112.00
1 month
92.11
Extreme 92.11
114.25
Current year
84.06
Extreme 84.06
115.97
1 year
62.55
Extreme 62.55
163.24
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 11-02-28
Director of Finance/CFO 47 22-09-05
President 48 12-12-31
Members of the board TitleAgeSince
Director/Board Member 65 18-05-31
Director/Board Member 75 20-06-30
Director/Board Member 67 19-12-10
More insiders
Date Price Change Volume
24-03-28 106.6 -3.64% 3 955 926
24-03-27 110.6 +2.96% 4,575,169
24-03-26 107.4 -2.69% 4,151,787
24-03-25 110.4 +4.70% 3,569,441
24-03-22 105.4 +1.29% 2,037,299

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
110.6 USD
Average target price
134.1 USD
Spread / Average Target
+21.27%
Consensus
  1. Stock
  2. Equities
  3. Stock Moderna, Inc. - Nasdaq